Concepedia

Author

Heather Wray

AstraZeneca (Sweden)

Also Known As

H Wray, H. WESLEY WRAY, H. Wray, Heather Wray

32

Publications

1.2K

Citations

13

H-Index

28

Concepts

All Affiliations

AstraZeneca (Sweden)Quotient Clinical (United Kingdom)Loughborough UniversityRoyal Veterinary CollegeWaltham Centre for Pet Nutrition
HW

About

Heather Wray is an author at AstraZeneca (Sweden) specializing in medicine, pharmacotherapy, and pulmonary disease.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

820

2

Gastroenterology

2

2

39

3

Public Health

1

1

564

4

Allergy

1

1

81

5

Health Policy

1

1

12

Heather Wray

×

15

Publications

1.1K

Citations

13

H-Index

YearCitations

Quinidine Syncope

Arthur Selzer, Heather Wray

Circulation

1964

564

A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis

Anthony De Soyza, Ian Pavord, J.S. Elborn,

European Respiratory Journal

2015

103

The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD

A. Kirsten, Karin Förster, E. Radeczky,

Pulmonary Pharmacology & Therapeutics

2015

86

Effects of an oral MMP-9 and -12 inhibitor, AZD1236, on biomarkers in moderate/severe COPD: A randomised controlled trial

Ronald Dahl, Ingrid Louise Titlestad, Ari Lindqvist,

Pulmonary Pharmacology & Therapeutics

2012

81

Plasma concentrations of inflammatory markers in previously laminitic ponies

Heather Wray, Jonathan Elliott, Simon Bailey,

Equine Veterinary Journal

2012

59

Combined scintigraphic and pharmacokinetic investigation of enteric‐coated mesalazine micropellets in healthy subjects

Ian R. Wilding, Christoph Behrens, Sarah Tardif,

Alimentary Pharmacology & Therapeutics

2003

42

Safety and tolerability of an oral MMP-9 and -12 inhibitor, AZD1236, in patients with moderate-to-severe COPD: A randomised controlled 6-week trial

H Magnussen, Henrik Watz, Anne Kirsten,

Pulmonary Pharmacology & Therapeutics

2011

38

The effect of exercise on plasma concentrations of inflammatory markers in normal and previously laminitic ponies

Nicola J. Menzies‐Gow, Heather Wray, Simon Bailey,

Equine Veterinary Journal

2013

26

Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers

Marie Cullberg, Cecilia Arfvidsson, Bengt Larsson,

Drugs in R&D

2018

24

Pharmacoscintigraphic Assessment of the Regional Drug Absorption of the Dual Angiotensin‐Converting Enzyme/Neutral Endopeptidase Inhibitor, M100240, in Healthy Volunteers

Nancy Martin, Kathryn R. Collison, Louis L. Martin,

The Journal of Clinical Pharmacology

2003

23

Page 1